Business
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has today announced its corporate name change to SPT Labtech effective from January 6, 2020.
The U.S. Senate confirmed Hahn as the new commissioner Thursday in a 72-18 vote.
House Speaker Nancy Pelosi’s drug pricing reform bill passed the House of Representatives in a mostly party-line vote and will now head to the U.S. Senate, where its chances of moving forward in the Republican-led chamber are slim.
Scientific collaboration to study the anti-inflammatory activity of gut beneficial bacteria, more specifically Christensenella for which LNC Therapeutics holds an exclusive worldwide license
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
Inceptua announced that Stefan Fraenkel has been appointed CEO effective 1 January 2020.
Start Codon cohort companies to receive One Nucleus membership benefits
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Karuna’s work is primarily focused on psychosis related to schizophrenia and late-stage Alzheimer’s disease, as well as analgesic effects for pain.
Aligos Chief Executive Officer Lawrence Blatt told BioSpace that the different assets in development address different components of the infection.